Literature DB >> 12480313

Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur.

Lin Zhang1, Daniel L Parsons, Christine Navarre, Uday B Kompella.   

Abstract

The objective of this study was to develop sustained release Poloxamer 407 (P407) gel formulations of ceftiofur for treating foot infections in cattle. The formulations contained 25-35% (w/v) P407 alone or with polyvinyl pyrrolidone (PVP), carboxy methylcellulose (CMC), or hydroxylpropyl methylcellulose (HPMC) as an additive. The in-vitro release profiles of ceftiofur from the P407 formulations and the gel dissolution profiles were obtained simultaneously. Ceftiofur release followed zero order kinetics and correlated well with the weight percentage of P407 dissolved, indicating that the overall rate of release of ceftiofur is controlled by dissolution of the P407. An increase in P407 content from 25 to 35% resulted in a decrease in the rate of ceftiofur release. However, it appears that other factors may have also affected the drug release rate. Inclusion of PVP, CMC, and HPMC in the gel decreased the rate of release of ceftiofur to some extent. A decrease in the temperatures of the release medium decreased the release rate of ceftiofur, but not the rate of gel dissolution. The pH of the release medium showed a very slight effect on the release of ceftiofur and did not affect gel dissolution due to the non-ionic nature of P407.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12480313     DOI: 10.1016/s0168-3659(02)00273-0

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  39 in total

1.  In vitro and in vivo characteristics of a thermogelling rectal delivery system of etodolac.

Authors:  Nahla S Barakat
Journal:  AAPS PharmSciTech       Date:  2009-05-29       Impact factor: 3.246

2.  A floating hydrogel system capable of generating CO2 bubbles to diminish urinary obstruction after intravesical instillation.

Authors:  Tingsheng Lin; Yifan Zhang; Jinhui Wu; Xiaozhi Zhao; Huibo Lian; Wei Wang; Hongqian Guo; Yiqiao Hu
Journal:  Pharm Res       Date:  2014-04-22       Impact factor: 4.200

3.  Thermoreversible nasal in situ gel of venlafaxine hydrochloride: formulation, characterization, and pharmacodynamic evaluation.

Authors:  Mandar J Bhandwalkar; Amelia M Avachat
Journal:  AAPS PharmSciTech       Date:  2012-12-11       Impact factor: 3.246

4.  Development and characterization of mucoadhesive in situ nasal gel of midazolam prepared with Ficus carica mucilage.

Authors:  Shyamoshree Basu; Amal Kumar Bandyopadhyay
Journal:  AAPS PharmSciTech       Date:  2010-08-04       Impact factor: 3.246

5.  Assessment of PLGA-PEG-PLGA copolymer hydrogel for sustained drug delivery in the ear.

Authors:  Liang Feng; Jonette A Ward; S Kevin Li; Gaurav Tolia; Jinsong Hao; Daniel I Choo
Journal:  Curr Drug Deliv       Date:  2014       Impact factor: 2.565

6.  Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials.

Authors:  Muhammad Sajid Hamid Akash; Kanwal Rehman; Ni Li; Jian-Qing Gao; Hongying Sun; Shuqing Chen
Journal:  Pharm Res       Date:  2012-08-21       Impact factor: 4.200

7.  Thermosensitive Pluronic hydrogel: prolonged injectable formulation for drug abuse.

Authors:  Katayoun Derakhshandeh; Mahtab Fashi; Seyedalireza Seifoleslami
Journal:  Drug Des Devel Ther       Date:  2010-09-24       Impact factor: 4.162

8.  Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab.

Authors:  Puneet Tyagi; Matthew Barros; Jeffrey W Stansbury; Uday B Kompella
Journal:  Mol Pharm       Date:  2013-07-08       Impact factor: 4.939

9.  Comparative study to investigate the effect of meloxicam or minocycline HCl in situ gel system on local treatment of periodontal pockets.

Authors:  Abeer Ahmed Kassem; Fatma Ahmed Ismail; Vivian Fahim Naggar; Elsayed Aboulmagd
Journal:  AAPS PharmSciTech       Date:  2014-05-16       Impact factor: 3.246

10.  Formulation of immediate release pellets containing famotidine solid dispersions.

Authors:  Mohamed Abbas Ibrahim; Mahmoud El-Badry
Journal:  Saudi Pharm J       Date:  2013-02-16       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.